Innate Pharma Announces 2026 Financial Calendar

Innate Pharma SA, listed on Euronext Paris and Nasdaq, has unveiled its financial schedule for 2026. The company will release its 2025 financial results on March 26. Revenue and cash position for the first quarter will be disclosed on May 13, followed by the Annual General Shareholders Meeting on May 21. Half-year financial statements are set for publication on September 17, with third quarter figures revealed on November 5. All reports will be made available before the market opens CET. Investors can find comprehensive information on Innate's website under the Investors section.

As a biotechnology company, Innate Pharma specializes in immunotherapies for cancer, leveraging expertise in antibody engineering and target identification. Additionally, Innate maintains collaborations with major firms like Sanofi and AstraZeneca. Headquartered in Marseille, the company continues to advance its pipeline of innovative therapeutics.